1,488 reports of this reaction
1.3% of all UPADACITINIB reports
#19 most reported adverse reaction
ILLNESS is the #19 most commonly reported adverse reaction for UPADACITINIB, manufactured by AbbVie Inc.. There are 1,488 FDA adverse event reports linking UPADACITINIB to ILLNESS. This represents approximately 1.3% of all 110,317 adverse event reports for this drug.
UPADACITINIB has an overall safety score of 85 out of 100. Patients taking UPADACITINIB who experience illness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ILLNESS is a less commonly reported adverse event for UPADACITINIB, but still significant enough to appear in the safety profile.
In addition to illness, the following adverse reactions have been reported for UPADACITINIB:
The following drugs have also been linked to illness in FDA adverse event reports:
ILLNESS has been reported as an adverse event in 1,488 FDA reports for UPADACITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ILLNESS accounts for approximately 1.3% of all adverse event reports for UPADACITINIB, making it a notable side effect.
If you experience illness while taking UPADACITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.